<?xml version="1.0" encoding="UTF-8"?>
<p id="Par42">We designed the study as a safety-oriented trial and considered enrolling a cohort of up to 32 participants to: 
 <list list-type="order">
  <list-item>
   <p id="Par43">Comprehensively characterise the safety profile of nivolumab and ipilimumab co-administration in patients with early-stage HCC;</p>
  </list-item>
  <list-item>
   <p id="Par44">Preliminarily document the efficacy of treatment to inform subsequent efficacy-testing in a future adequately powered trial;</p>
  </list-item>
  <list-item>
   <p id="Par45">Obtain adequate information regarding the disease-modulating effects from treatment reflected by the proposed exploratory endpoints.</p>
  </list-item>
 </list>
</p>
